NASA awards $5 million to artificial retina development efforts

Article

key opens lock in eye

LambdaVision and its partner SpaceTango have been selected by National Aeronautics and Space Administration (NASA) to receive a $5 million reward toward the development of the first protein-based artificial retina. Researchers hope the novel treatment will help blind patients and those with significant sight loss due to advanced retinitis pigmentosa (RP) regain sight. The artificial retina offers secondary application as well in age-related macular degeneration (AMD) andother retinal degenerative diseases, according to the company.

The protein-based, artificial retinas produced in the program imitate human photoreceptors’ light-absorbing properties. They are capable of awakening deteriorating retinas of blind and nearly blind patients, thereby regaining sight.

Related: Companies offer CE, other resources amid coronavirus pandemic

The award includes a series of flights to the International Space Station (ISS) U.S. national laboratory over a three-year period to improve on-orbit processes relating to the production of artificial retinas. LambdaVision and SpaceTango are focused on using the microgravity environment to optimize manufacturing parameters for the assembly of retinal implants.

Artificial retinas are already produced on Earth through a layer-by-layer construction process, but researchers at LambdaVision believes microgravity may reduce the amount of materials required, thereby lowering costs and accelerating manufacturing.

Once the process is legitimized and production goals are reached, it could lead the way for more space-manufactured medical products to be developed.

In a statement, Twyman Clements, co-founder and chief executive officer of SpaceTango says, “As we explore the seemingly immense ways in which microgravity can benefit the development and production of a wide range of products, our long-term collaboration with LambdaVision continues to provide us with valuable learnings that might one day help some patients regain sight and may also lead to other important production discoveries.”

More by Brooke Beery: COVID-19: Key metrics ranked by state

Recent Videos
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Clark Chang, OD, MSA, MSc, FAAO, discussed the complexities of diagnosing keratoconus in his Rapid Fire presentation given at the American Academy of Optometry 2024 meeting.
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, details the ease of genetic testing when diagnosing patients or reassessing a patient's diagnosis.
Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium
© 2024 MJH Life Sciences

All rights reserved.